Vera Therapeutics Says TRUTAKNA Met All ORIGIN 3 Endpoints
The company said TRUTAKNA met the primary and all prespecified endpoints in IgA nephropathy, with safety generally comparable to placebo. It plans to file a supplemental BLA in Q4 2026.
Vera Therapeutics said final efficacy results from ORIGIN 3 showed TRUTAKNA met the primary endpoint and all prespecified endpoints in IgA nephropathy. Safety was generally comparable to placebo. The company plans to file a supplemental BLA in Q4 2026.